Yüklüyor......
Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter’s Syndrome
INTRODUCTION: To improve outcomes of patients with Richter's syndrome (RS) and relapsed/refractory chronic lymphocytic leukemia (CLL), we modified the oxaliplatin and cytarabine doses of the oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR1) regimen for this phase I-II study (OFAR2). P...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4180513/ https://ncbi.nlm.nih.gov/pubmed/23810245 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.03.012 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|